Loading, please wait...
This program aims to help pharmacists maintain and enhance professional competencies to ensure optimal medication therapy outcomes and patient safety from the use of long-acting injectable antipsychotics.
Fee
$0.00
CE Hours
1.00
CE Units
0.100
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
|
Shenandoah University Bernard J. Dunn School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
To receive credit the following items must be completed
1. Register for the event through supharmacy.learningexpressce.com
2. Attend the entire activity
3. Complete all relevant learning assessments
4. Complete an activity evaluation through supharmacy.learningexpressce.com
Support/Credits
No external funding has been obtained for this activity. The speakers have no conflicts of interest to disclose and state that the decisions made for program development were free of the control of a commercial interest.
Objectives
- Summarize the evidence available for the use of second-generation long-acting injectable antipsychotic medications related to schizophrenia
- Analyze the risks and benefits of second-generation long-acting injectable antipsychotic medications for the management of schizophrenia
- Evaluate guideline recommendations for using second-generation long-acting injectable antipsychotic medications in schizophrenia
Speaker(s)/Author(s)
|
Larissa Nguy, PharmD
|
Activity Number
0101-0000-20-001-H01-P
CE Hours
1.00
Location
Novant Health Systems